Overview

A Phase Ib/ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-25

Target enrollment:

Participant gender:

Summary

This trial is an open-label, multicenter phase Ib/II clinical study of LBL-024 combination therapy in patients with platinum-resistant ovarian cancer (OC),To evaluate the efficacy and safety of LBL-024 combination therapy in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC) patients.

Phase:

PHASE1

Details

Lead Sponsor:

Nanjing Leads Biolabs Co.,Ltd

Treatments:

Injections
Paclitaxel